Common variable immunodeficiency (CVID) is a rare immune deficiency, characterized by low levels of serum IgG, IgA and/or IgM, with loss of antibody production. The diagnosis is most commonly made in adults between the ages of 20 and 40, but both children and older adults can be found to have this immune defect. The range of clinical manifestations is broad, including acute and chronic infections, inflammatory and autoimmune disease and an increased incidence of cancer and lymphoma. For all these reasons, the disease phenotype is both heterogeneous and complex. Contributing to the complexity is that patient cohorts are generally small, criteria used for diagnosis vary, and the doses of replacement immune globulin differ. In addition, routines for monitoring patients over the years and protocols for using other biologic agents for complications have not been clarified or standardized. In the past few years, data from large patient registries have revealed that both selected laboratory markers and clinical phenotyping may aid in dissecting groups of subjects into biologically relevant categories. This review presents my approach to the diagnosis and treatment of patients with CVID, with suggestions for the use of laboratory biomarkers and means of monitoring patients over time.
Abstract:
Common variable immunodeficiency (CVID) is a rare immune deficiency, characterized by low levels of serum IgG, IgA and/or IgM, with loss of antibody production. The diagnosis is most commonly made in adults between the ages of 20 and 40, but both children and older adults can be found to have this immune defect. The range of clinical manifestations is broad, including acute and chronic infections, inflammatory and autoimmune disease and an increased incidence of cancer and lymphoma. For all these reasons, the disease phenotype is both heterogeneous and complex. Contributing to the complexity is that patient cohorts are generally small, criteria used for diagnosis vary, and the doses of replacement immune globulin differ. In addition, routines for monitoring patients over the years and protocols for using other biologic agents for complications have not been clarified or standardized. In the past few years, data from large patient registries have revealed that both selected laboratory markers and clinical phenotyping may aid in dissecting groups of subjects into biologically relevant categories. This review presents my approach to the diagnosis and treatment of patients with CVID, with suggestions for the use of laboratory biomarkers and means of monitoring patients over time.
Introduction:
CVID is the most common clinically important primary immune deficiency disease due to a prevalence, estimated at between 1 in 25,000 to 50,000
Caucasians, complications, hospitalizations and requirement for lifelong replacement immune globulin therapy(1, 2). Unlike many genetic immune defects, the majority of subjects diagnosed with CVID are adults between the ages of 20 and 40 years, although many are found outside this age range.
Although the syndrome was first described more than 50 years ago(3), the diagnosis is still commonly delayed by 6-8 years, even after the onset of characteristic symptoms. A number of reports of cohorts of subjects with CVID have appeared(1, [4] [5] [6] [7] [8] . In appropriate doses, immunoglobulin (Ig) replacement reduces the incidence of acute bacterial infections, however, Ig does not address the more problematic of complications that have now emerged as the foremost concerns, including chronic lung disease, systemic granulomatous disease, autoimmunity, lymphoid hyperplasia and infiltrative disease, gastrointestinal disease, and the development of cancer. These complications now appear to be the major cause of morbidity and death in CVID(1, 9). This review is intended as a personal summary of how I assess patients at the outset, and outline how one may monitor for and treat some of these challenging complications.
Diagnosis of CVID:
The diagnosis of common variable immune deficiency (CVID, International Classification of Diseases code, ICD 279.06) is often misused. It is defined as a genetic immune defect characterized by significantly decreased levels of IgG, IgA and/or IgM with poor or absent antibody production, with exclusion of genetic or other causes of hypogammaglobulinemia(1, 2, 9, 10). Based on the standard definition, antibody deficiency with normal immune globulin levels, or IgG deficiency alone, would not qualify for the diagnosis of CVID. As CVID is not always easily discerned from transient hypogammaglobulinemia of infancy, a general consensus is that this diagnosis should not be applied until after the age of 4.
This allows time for the immune system to mature, and if necessary, to consider the possibility of other genetic primary immune defects. However, the published criteria still leave open rather wide boundaries. First laboratory standards for normal ranges differ; in addition, using the 95% percentile for immune globulins, allow 2.5% of normal subjects to fall below the normal range. Sometimes forgotten, the additional necessary criteria for CVID also include a proven lack of specific IgG antibody production. This is usually demonstrated by lack of IgG responses (not attaining laboratory-defined protective levels) to two or more protein vaccines such as tetanus or diphtheria toxoids, Haemophilus conjugate, measles, mumps and rubella vaccines, and also by lack of response to pneumococcal polysaccharide vaccines. Other options for protein antigens include hepatitis A or B vaccines or varicella, either after vaccination or disease exposure. Examining blood for pertinent isohemagglutins, is another a common means of testing (mostly) IgM anticarbohydrate antibody production in older children and adults. While extensive antibody testing is not as important for subjects with very low serum IgG (potentially 150 mg/dl or less), those with higher levels of serum IgG (450-600mg/dl) and especially those with only minimally reduced serum IgA, require more extensive evaluation. It is more likely that these subjects have preservation of IgG antibody production and are therefore less likely to benefit from Ig therapy. A suggested template for such analyses is given on Table 1 .
Demonstration of persistence of IgG antibody at 6 months after vaccination can be important to prove sustained antibody production in some cases. The many reasons for a very thorough evaluation before diagnosing CVID, include the facts that the diagnosis of CVID impacts short and long term insurance coverage, influences the outcome of all subsequent medical encounters, and may alter school and job choices and other life decisions, i.e. family planning and travel. In addition, if replacement Ig therapy is initiated without a compete evaluation and the use of this therapy is later questioned, it must be stopped for about 5 months before such an evaluation can be performed.
Immune globulin replacement:
The primary treatment of CVID is replacement of antibody, achieved by either intravenous (IV) or subcutaneous (SQ) route of immune globulin (Ig), usually in doses of 400 to 600 mg/kg body weight a month (11 The goal of Ig therapy is to prevent infections, however, the target trough serum IgG to attain, varies depending on the baseline level of IgG. For a subject with a baseline serum IgG of less than 100 mg/dl, a suggested trough level would be at least 600 mg/dl, but for a subject with an initial IgG of 300 mg/dl with no functional antibody, the required trough level might be 900 mg/dl to supply the minimum "normal" level of functional Ig. Immune globulin is often given in the home. Both IV and SQ methods provide both safe and effective replacement(18) (19) (11); convenience to the patient can best guide these choices. In our practice, the majority of our patients are given 400 mg/dl IV once per month; 10 to 15% are using SQ treatment in pro-rated doses given more frequently. Attention is given to those with lung disease or previous autoimmunity to be sure that more than adequate "trough" levels are Severe bacterial infections such as empyema, sepsis, meningitis, or osteomyelitis, often with the same organisms, are less common but are noted in all series. In our current cohort, 90% of 476 subjects have had one or more of these infectious complications. However, subjects with CVID have other less well understood inflammatory, autoimmune or neoplastic conditions, as outlined for our cohort, on Table 2 . While the incidence of these complications appear to vary in different countries,(1) they appear in all cohorts so far examined. The ramifications and treatment of these complications are described below. brain may be involved (27, (33) (34) (35) . The granuloma in CVID are variously wellformed, non caseating, and may contain contain non-necrotizing epithelioid and giant cells. While organisms are sought, these are very rarely found. In our series of 37 patients, 8.1% of our CVID subjects, the median age at diagnosis of CVID was 26 (2 -59). 14 had granulomas 1 -18 years before diagnosis of CVID; in 6 the detection of granulomas coincided with this diagnosis; for 17, granulomas were documented later. 54% had lung granulomas, 43% in lymph nodes and 32% in liver (31) . For unclear reasons, subjects with granulomatous disease are also much greater risk for autoimmune disease (almost always immune thrombocytopenia or autoimmune hemolytic anemia) than CVID subjects who do not have this pathology; for example, 54% of our patients with known granulomatous disease have had autoimmune disease. As described below, these subjects are also almost always those who have very few circulating, isotype switched memory B cells (36) . In some of these patients, an intense lymphoid infiltration accompanies the granulomas in lungs, leading to what has been termed "granulomatous lymphocytic interstitial lung disease," (29, 37 ) the presence of which is prognostic of a poor outcome (37) . A recent study reported a median survival of 13.7 years in CVID patients with granulomatous/lymphoid interstitial infiltrates, as compared to 28.8 years in those without this complication (29) .
Chronic Lung
HHV8 has been proposed to play a role of in the development of granulomatous disease in CVID (38) prescribe 200-400 mg a day (or range 3.5 to 6.5 mg/kg) of hydroxycloroquine, based on its mechanistic roles in reducing toll like receptor responses, antigen presentation, and its use in autoimmunity and sarcoidosis (39, 40) . For pulmonary granuloma, twice daily-inhaled beclomethasone is also prescribed.
Higher doses of IVIG have been found in one instance to aid in controlling lymphoid interstitial disease and granuloma (41, 42) but this does not seem to be a universal experience. Some years ago, work showed that some CVID patients had elevated serum levels of TNF-alpha and soluble TNF receptors (43) . Later, Mullighan reported granuloma in 20 of 90 patients with CVID (22%); 8 of these had an unusual TNF-alpha allele (TNF +488A)(28), but TNF-alpha production or levels were not actually examined. On this basis, and suggestive earlier work in sarcoidosis, TNF-alpha inhibitors (infliximab or etanercept) have been used in subjects with CVID with granuloma, with benefit in some cases (35, 44, 45) ; however, no controlled trials have been performed. I have had limited experience using TNF inhibitors for granulomatous disease; in 2 cases (both with granuloma in lung) it was not helpful but both patients had substantial lung defects.)
Lymphoid infiltrates in the lung leading to lymphoid interstitial pneumonia or follicular bronchitis/bronchiolitis without granuloma are equally challenging, as these lead to cough, shortness of breath, alveolar damage and ultimately, the need for oxygen therapy. Due to scarring and the predominance of T cells in the lung infiltrate (as shown in Figure 1 ,) cyclosporine has also been used with benefit (125 mg a day; serum level 76ng/ml) (46) . We have used cyclosporine in two subjects, with some stabilization of lung function for 4 years, but both succumbed to respiratory insufficiency, complicated by fatal acute hemolytic anemia in one of these subjects (31).
Autoimmunity:
Other complications resulting from immune dysregulation in CVID include autoimmune disease in up to 25%, mostly immune thrombocytopenia purpura (ITP), autoimmune hemolytic anemia (AIHA) or both (Evans syndrome) or more rarely, autoimmune neutropenia (47, 48).
( (66) . Helicobacter pylori infection has been associated with gastritis(53).
Aside from bacterial and parasitic infections, inflammatory bowel disease remains a significant problem in 19%-32% (6, 65) . Dissecting infectious from inflammatory disease is not always simple; both can lead to chronic even are far commoner than homozygous mutations and we and others have found that these are associated with both autoimmunity and lymphoid hyperplasia.
Whether this is due to the generation of abnormal signals or haploinsufficiency, has not been clarified (86, 87) . However, since the same mutations are routinely found in normal family members and sometimes in normal blood donors, testing for TACI mutations in patients is neither diagnostic of CVID nor predictive of immune deficiency in the future. For this reason, I do not recommended it for either of these purposes.
Survival, Clinical phenotypes and Biomarkers:
In an earlier report on CVID, 56 of 248 (23%) of subjects died over a follow-up period of 1-20 years (mean 7.5 years.) Compared to age-matched controls, the survival was significantly reduced, males at 64% as compared to 92% for controls, and 67% for females, with controls expecting 94% survival for the same periods of time(5).
These outcomes were similar to a report of 240 patients in the United Kingdom(4) in which over a 25 year period, 30% of subjects died. (5) The main causes of death in both studies include chronic respiratory tract insufficiency, destructive granulomatous organ involvement, liver disease, malnutrition due to gastrointestinal pathology, uncontrolled autoimmune disease and lymphoma
(1, 9).
In more recent years the overall survival of subjects with CVID appears improved, very likely due to the now standard doses of replacement Ig. Of the 334 CVID subjects collected from the ESID Registry, 51 subjects (15%) died over a longer mean follow-up period (22.5 years.) However, other factors appear important in survival as revealed by examination of these data. While about half of the patients had infections as the only manifestation, others with one or more of the other complications outlined above (autoimmunity, gastrointestinal disease, lymphoid hyperplasia, splenomegaly, granulomatous disease, cancer or non-Hodgkin's lymphoma) had diminished survival(1).
While a very low initial serum IgG level might be the most logical predictor for complications, there was no association found between the level of the serum IgG level at diagnosis and severe infections (including pneumonia), a higher incidence of lung disease, or increased mortality. Strangely, neither age at onset of symptoms, age at diagnosis, nor length of diagnostic delay was related to increased mortality.
These registry data illustrate the need for additional biologically relevant biomarkers to guide both evaluation and treatment in CVID. Previous studies showed that poorer T cell functions, reduced lymphocyte counts, very low numbers of B cells, and reduced numbers of both CD4+ T cells, and
CD45RA+CCR7+CD4+T (88) is no current consensus. Chest X-rays are not as revealing as HRCT, so it is reasonable to obtain this at baseline referral. However, radiosensitivity has been demonstrated in CVID (99, 100) , and for a younger subject, yearly or every 2-year examinations, especially in concert with other X-ray procedures, could lead to excessive radiation exposure over time (101) . Authorship:
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